Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $88,964.42 in Stock

Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Ag Postfinance sold 286,982 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the sale, the insider now owns 5,118,627 shares in the company, valued at approximately $1,586,774.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ag Postfinance also recently made the following trade(s):

  • On Friday, February 9th, Ag Postfinance sold 236,155 shares of Cytori Therapeutics stock. The shares were sold at an average price of $0.34, for a total value of $80,292.70.

Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) traded up $0.05 during midday trading on Wednesday, reaching $0.36. The company’s stock had a trading volume of 1,821,195 shares, compared to its average volume of 2,367,844. Cytori Therapeutics Inc has a 12-month low of $0.22 and a 12-month high of $2.13. The firm has a market capitalization of $10.89, a PE ratio of -0.40 and a beta of 3.11.

A number of hedge funds and other institutional investors have recently made changes to their positions in CYTX. Vanguard Group Inc. raised its stake in Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares in the last quarter. Sabby Management LLC raised its stake in Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its stake in Cytori Therapeutics by 134.0% during the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares in the last quarter. Hedge funds and other institutional investors own 10.82% of the company’s stock.

Several brokerages have issued reports on CYTX. Zacks Investment Research cut Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Maxim Group set a $4.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a research note on Tuesday. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/cytori-therapeutics-inc-cytx-major-shareholder-sells-88964-42-in-stock.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply